Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) shares dropped 2.9% during trading on Monday . The stock traded as low as C$2.69 and last traded at C$2.69. Approximately 78,544 shares were traded during trading, an increase of 13% from the average daily volume of 69,555 shares. The stock had previously closed at C$2.77.
Wall Street Analyst Weigh In
Separately, Alliance Global Partners raised shares of Medexus Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Four analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of C$4.57.
Check Out Our Latest Stock Report on Medexus Pharmaceuticals
Medexus Pharmaceuticals Price Performance
The company has a market capitalization of C$86.77 million, a PE ratio of 134.50 and a beta of 2.55. The company's fifty day moving average is C$2.89 and its 200-day moving average is C$2.79.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
